Company Announcements

Unlike some other biotech companies, Enlivex has adopted a dual strategy that combines a clinical-stage immunotherapy platform focused on quality longevity therapeutics, with a treasury model anchored in the Rain decentralized prediction markets protocol. The dual-engine structure provides public market investors exposure to emerging prediction markets infrastructure while continuing to advance its clinical development programs focused on improving healthspan and quality of life, reports Enlivex.

The company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis.

"Our clinical engine continues to progress with Allocetra™ and its potential to restore mobility and independence in aging populations. In parallel, our treasury engine establishes exposure to prediction markets infrastructure through the Rain protocol, creating a capital strategy designed to align long-term shareholder value with the growth of decentralized forecasting markets," said Shai Novik, Executive Chairman of Enlivex. "Together, these two engines position Enlivex to pursue innovation in quality longevity therapeutics while developing an innovative treasury model for a public company, which contributed to strong profitability for Enlivex in 2025 based on the unrealized appreciation in the Company’s treasury and treasury-related derivative assets."

To learn more about Enlivex's treasury strategy and read the full earnings report, click here.

Featured image from Enlivex.

This content was originally published on Benzinga. Read further disclosures here.

This post contains sponsored content and was created in collaboration with a third-party partner. Benzinga is a publisher and does not provide personalized investment advice or act as a broker or dealer. This content is for informational purposes only and is not intended to be investing advice or an offer or solicitation to buy or sell any security.